Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 7.91% is 341% above its 5-year average of -3.29%, around the middle of its 5-year range (-24.19%–26.28%).
56.36% above its 12-month average of 5.06%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 2.85%.
NET PROFIT MARGIN
7.91%
NET PROFIT MARGIN AVG TTM
5.06%
NET PROFIT MARGIN AVG 3Y
1.02%
NET PROFIT MARGIN AVG 5Y
-3.29%
NET PROFIT MARGIN AVG 10Y
-7.82%
NET PROFIT MARGIN AVG 15Y
-12.27%
NET PROFIT MARGIN AVG 20Y
-626.54%
CURRENT VS TTM AVG
+56.36%
CURRENT VS 3Y AVG
+676.50%
CURRENT VS 5Y AVG
+340.58%
CURRENT VS 10Y AVG
+201.18%
CURRENT VS 15Y AVG
+164.47%
CURRENT VS 20Y AVG
+101.26%
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+2360.00%
vs the sector median at left
Vericel Corporation
Market Cap
$2.05B
Net Profit Margin
7.91%
TTM Avg
5.06%
3Y Avg
1.02%
5Y Avg
-3.29%
Market Cap
$2.06B
Net Profit Margin
-268385.71%
TTM Avg
-9751.05%
3Y Avg
-6580.61%
5Y Avg
-4774.06%
Market Cap
$2.06B
Net Profit Margin
-544.06%
TTM Avg
-44935.33%
3Y Avg
-43227.84%
5Y Avg
-31022.63%
Market Cap
$2.08B
Net Profit Margin
-36.51%
TTM Avg
-21.30%
3Y Avg
-316.14%
5Y Avg
-299.31%
Market Cap
$2.02B
Net Profit Margin
-40.90%
TTM Avg
5.22%
3Y Avg
-37.29%
5Y Avg
-215.44%
Market Cap
$2.02B
Net Profit Margin
-51.73%
TTM Avg
-140.08%
3Y Avg
-143.59%
5Y Avg
-315.66%
Market Cap
$2.02B
Net Profit Margin
100.84%
TTM Avg
51.96%
3Y Avg
-5.31%
5Y Avg
-103.82%
Market Cap
$2.11B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1032.53%
5Y Avg
-880.74%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.05B | 7.91% | 5.06% | 1.02% | -3.29% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -268385.71% | -9751.05% | -6580.61% | -4774.06% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -544.06% | -44935.33% | -43227.84% | -31022.63% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 6.00% | 4.60% | 4.69% | 7.56% |
| Alvotech (ALVO)vs › | $2.08B | -36.51% | -21.30% | -316.14% | -299.31% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -40.90% | 5.22% | -37.29% | -215.44% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -51.73% | -140.08% | -143.59% | -315.66% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 100.84% | 51.96% | -5.31% | -103.82% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 0.00% | 0.00% | -1032.53% | -880.74% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
6.0%
Net Profit Margin
7.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 2.85% |
| 2026-03-31 | -9.21% |
| 2025-12-31 | 25.01% |
| 2025-09-30 | 7.52% |
| 2025-06-30 | -0.87% |
| 2025-03-31 | -21.38% |
| 2024-12-31 | 26.28% |
| 2024-09-30 | -1.56% |
| 2024-06-30 | -8.89% |
| 2024-03-31 | -7.53% |
| 2023-12-31 | 19.99% |
| 2023-09-30 | -8.03% |
| 2023-06-30 | -10.93% |
| 2023-03-31 | -18.27% |
| 2022-12-31 | 11.24% |
| 2022-09-30 | -17.06% |
| 2022-06-30 | -24.19% |
| 2022-03-31 | -19.66% |
| 2021-12-31 | 9.53% |
| 2021-09-30 | -14.29% |
| 2021-06-30 | -9.58% |
| 2021-03-31 | -9.51% |
| 2020-12-31 | 27.02% |
| 2020-09-30 | 11.22% |
| 2020-06-30 | -41.32% |
| 2020-03-31 | -17.64% |
| 2019-12-31 | 24.12% |
| 2019-09-30 | 11.38% |
| 2019-06-30 | -75.68% |
| 2019-03-31 | -13.04% |
| 2018-12-31 | 16.73% |
| 2018-09-30 | -4.75% |
| 2018-06-30 | -24.46% |
| 2018-03-31 | -42.49% |
| 2017-12-31 | 1.23% |
| 2017-09-30 | -37.92% |
| 2017-06-30 | -14.09% |
| 2017-03-31 | -104.45% |
| 2016-12-31 | -37.51% |
| 2016-09-30 | -61.08% |
| 2016-06-30 | -23.74% |
| 2016-03-31 | -25.87% |
| 2015-12-31 | -31.84% |
| 2015-09-30 | -39.05% |
| 2015-06-30 | -15.84% |
| 2015-03-31 | -44.82% |
| 2014-12-31 | -16.12% |
| 2014-09-30 | -71.62% |
| 2014-06-30 | -104.65% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | -36450.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | -162966.67% |
| 2013-03-31 | -69300.00% |
| 2012-12-31 | -35000.00% |
| 2012-09-30 | -67044.44% |
| 2012-06-30 | 0.00% |
| 2012-03-31 | -472750.00% |
| 2011-12-31 | -553.37% |
| 2011-09-30 | -21488.89% |
| 2011-06-30 | 0.00% |
| 2011-03-31 | -55422.22% |
| 2010-12-31 | 0.00% |
| 2010-09-30 | 0.00% |
| 2010-06-30 | 24357.14% |
| 2010-03-31 | 0.00% |
| 2009-12-31 | -28593.75% |
| 2009-09-30 | -5206.85% |
| 2009-06-30 | -5736.23% |
| 2009-03-31 | -6848.28% |
| 2008-12-31 | -14653.57% |
| 2008-09-30 | -14492.59% |
| 2008-06-30 | -3263.76% |
| 2008-03-31 | -2499.01% |
| 2007-12-31 | -6157.14% |
| 2007-09-30 | -5804.60% |
| 2007-06-30 | -2926.67% |
| 2007-03-31 | -1737.60% |
| 2006-12-31 | -2674.05% |
| 2006-09-30 | -3900.96% |
| 2006-06-30 | -1309.76% |
| 2006-03-31 | -1911.34% |
| 2005-12-31 | -3540.17% |
| 2005-09-30 | -1937.78% |
| 2005-06-30 | -3500.00% |
| 2005-03-31 | -1328.97% |
| 2004-12-31 | -655.88% |
| 2004-09-30 | -1416.58% |
| 2004-06-30 | -1308.10% |
| 2004-03-31 | -600.96% |
| 2003-12-31 | -639.10% |
| 2003-09-30 | -946.00% |
| 2003-06-30 | -1564.57% |
| 2003-03-31 | -745.39% |
| 2002-12-31 | -1337.43% |
| 2002-09-30 | -2636.56% |
